Aligos Therapeutics presented positive long-term data at the EASL Congress 2026 showing that pevifoscorvir sodium monotherapy reduces the cccDNA reservoir in chronic hepatitis B patients, potentially enabling functional cure. About 40% of treated HBeAg+ patients had significant reductions in HBsAg, making them eligible for further antisense oligonucleotide (ASO) therapy. The combination of pevifoscorvir sodium with ASO ALG-170675 showed additive to synergistic antiviral effects, suggesting pevifoscorvir sodium could replace current standard treatments and play a key role in functional cure regimens. Further clinical development and regulatory progress are anticipated.
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
Ondo Finance has introduced the first tokenized stock representations backed by DTCC tokenized entitlements, joining major financial firms in a significant tokenization initiative. This move highlights Ondo's unique position in building infrastructur...
